MaGic
92 evidence topics · 12 sources
Objective
Objective of the randomized controlled period
Objective of the top-line results abstract
Objective of the open-label extension analysis
Objective of the minimal symptom expression analysis
Location and study date
Study dates and status in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Recruitment status | “Active, not recruiting” |
| Study start (actual) | “2024-02-23” |
| Primary completion (actual) | “2025-07-28” |
| Study completion (estimated) | “2028-10” |
| First posted | “2024-02-28” |
| Last update posted | “2026-07-27” |
Number of locations and trial identifiers in the ClinicalTrials.gov record
Trial initiation after FDA clearance of the investigational new drug application
Top-line results reported in September 2025
Study design
Study periods in the ClinicalTrials.gov record
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Study type | “Interventional” |
| Phase | “Phase 2” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
Randomization 1:1:1 to two claseprubart doses or placebo for 13 weeks
Design described at the release of top-line results
Design planned at trial initiation
Open-label extension entry, dosing, and follow-up of participants who declined
Eligibility criteria
Study population summarized in the poster
Inclusion criteria: age, weight, diagnosis, disease class, and MG-ADL score
Exclusion criteria: infection history, viral infections, and thymic disease
Exclusion criteria: prior and concomitant therapy
Exclusion criterion: antinuclear antibody titer
Exclusion of prior C5 complement inhibitor use
Treatment
Arms and interventions in the ClinicalTrials.gov record
| Arm | Day 1 | Week 1 to week 11 |
|---|---|---|
| Placebo comparator: placebo | “Day 1: IV infusion of placebo” | “Week 1 to Week 11: placebo administered SC every 2 weeks” |
| Experimental: claseprubart 300 mg Q2W | “Day 1: IV loading dose” | “Week 1 to Week 11: Claseprubart administered SC every 2 weeks” |
| Experimental: claseprubart 600 mg Q2W | “Day 1: IV loading dose” | “Week 1 to Week 11: Claseprubart administered SC every 2 weeks” |
Intravenous loading dose followed by subcutaneous dosing every 2 weeks
Loading dose by arm and subcutaneous volume
Treatment described at the release of top-line results
Open-label extension dosing for participants switching from placebo
Open-label extension dose unified to 300 mg every 2 weeks
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Registered primary outcome measure: treatment-emergent adverse events and serious adverse events to week 13
Safety and tolerability as the primary endpoint
Primary, key secondary, and key exploratory assessments
Registered secondary outcome measures: long-term safety, serum concentrations, CH50, and antidrug antibodies
Efficacy measure: Myasthenia Gravis Activities of Daily Living scale
Efficacy measure: Quantitative Myasthenia Gravis score
Efficacy measure: minimal symptom expression on MG-ADL and QMG
Efficacy measure: revised 15-item Myasthenia Gravis Quality of Life scale
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Participants in the pooled claseprubart group of the randomized period
Description of analysis sets
Mixed model for repeated measures for MG-ADL, QMG, and MGC
Logistic regression for minimal symptom expression and general linear model for MG-QoL-15r
One-sided and two-sided significance thresholds
Adjusted logistic regression for MG-ADL and QMG minimal symptom expression
Dual MG-ADL and QMG responder definition and endpoints
“A responder was defined as achieving an improvement in MG‐ADL ≥ 3 and QMG ≥ 4. Endpoints include proportion of dual MG‐ADL and QMG responders at Week 13, time to response, and proportion of responders sustaining response for at least 6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled analysis of the two dose groups in the open-label extension
Results
Participant disposition
Discontinuations in the placebo and 300 mg arms
Entry into the open-label extension and duration of dosing
Baseline characteristics
Demographic and disease characteristics by arm
| Characteristic | Placebo (N=22) | Claseprubart 300 mg Q2W (N=21) | Claseprubart 600 mg Q2W (N=22) |
|---|---|---|---|
| Age, mean (SD), years | “52.2 (16.5)” | “57.1 (13.7)” | “55.3 (12.0)” |
| Male, n (%) | “13 (59%)” | “14 (67%)” | “10 (45%)” |
| Weight, mean (SD), pounds | “195.0 (48.0)” | “192.5 (35.5)” | “179.0 (35.4)” |
| Duration of disease, median (range), years | “7.7 (0.4 – 21.2)” | “3.0 (0.5 – 22.1)” | “7.6 (1.0 – 37.3)” |
| MG-ADL score at baseline, mean (SD) | “8.5 (2.9)” | “8.2 (2.2)” | “8.4 (2.6)” |
| QMG score at baseline, mean (SD) | “14.2 (5.8)” | “12.2 (2.7)” | “12.2 (3.6)” |
| MG Composite score at baseline, mean (SD) | “15.0 (7.8)” | “16.3 (4.5)” | “16.0 (5.3)” |
| MG-QoL-15r score at baseline, mean (SD) | “14.3 (7.0)” | “15.4 (6.6)” | “14.9 (5.9)” |
| MGFA class II at screening, n (%) | “7 (32%)” | “11 (52%)” | “12 (55%)” |
| MGFA class III at screening, n (%) | “12 (55%)” | “10 (48%)” | “9 (41%)” |
| MGFA class IVa at screening, n (%) | “3 (14%)” | “0 (0%)” | “1 (5%)” |
| Prior thymectomy, n (%) | “8 (36%)” | “6 (29%)” | “7 (32%)” |
| Baseline corticosteroid use, n (%) | “19 (86%)” | “17 (81%)” | “20 (91%)” |
| One immunosuppressive therapy at baseline, n (%) | “11 (50%)” | “10 (48%)” | “12 (55%)” |
| More than one immunosuppressive therapy at baseline, n (%) | “11 (50%)” | “11 (52%)” | “10 (45%)” |
| FcRn use in prior 24 months, n (%) | “0 (0%)” | “1 (5%)” | “0 (0%)” |
| Prior complement use, n (%) | “0 (0%)” | “0 (0%)” | “0 (0%)” |
Efficacy results
Week 13 efficacy summary by arm with placebo-adjusted differences
| Measure at week 13 | Placebo (N=22) | Claseprubart 300 mg Q2W (N=21), absolute | Claseprubart 300 mg Q2W, placebo-adjusted (one-sided P) | Claseprubart 600 mg Q2W (N=22), absolute | Claseprubart 600 mg Q2W, placebo-adjusted (one-sided P) |
|---|---|---|---|---|---|
| MG-ADL mean change from baseline | “-2.8” | “-4.6” | “-1.8 (P=0.0113)” | “-5.4” | “-2.6 (P=0.0006)” |
| QMG mean change from baseline | “-2.0” | “-4.4” | “-2.4 (P=0.0144)” | “-4.5” | “-2.5 (P=0.0111)” |
| MSE | “14%” | “37%” | “23% (P=0.0550)” | “27%” | “13% (P=0.1031)” |
| MGC mean change from baseline | “-3.1” | “-8.7” | “-5.6 (P=0.0008)” | “-8.6” | “-5.5 (P=0.0008)” |
MG-ADL change from baseline at week 13 by arm
QMG change from baseline at week 13 by arm
Two-sided P values for MG-ADL and QMG at week 13
| Measure | Claseprubart 300 mg Q2W vs placebo, two-sided P | Claseprubart 600 mg Q2W vs placebo, two-sided P |
|---|---|---|
| MG-ADL | “P=0.0227” | “P=0.0013” |
| QMG | “P=0.0288” | “P=0.0222” |
Week 1 onset of MG-ADL and QMG improvement
Improvement of 5 points or more on MG-ADL and QMG at week 13
Dual MG-ADL and QMG responders at week 13
“Results: 63% of claseprubart patients had dual response improvement in MG‐ADL ≥ 3 and QMG ≥ 4, versus 14% for placebo (OR 29.00; p = 0.0006). Dual responders were seen as early as Week 1. The median time to response was Week 3. All claseprubart patients with dual response at Week 13 had maintained response for at least 6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MG-ADL minimal symptom expression at week 13
QMG minimal symptom expression at week 13
MG-ADL minimal symptom expression at week 13 in both dose groups
MGC placebo-adjusted change with 80% confidence intervals
Post hoc subgroup with baseline QMG score of 10 or higher
Open-label extension: sustained response through 65 weeks of treatment
Open-label extension: change from extension baseline to week 52 in the MG-ADL, QMG, and MGC panels
Open-label extension: week 4 response after switching from placebo
Open-label extension: serum concentration after two 600 mg doses
Health-related quality of life and patient-reported outcomes
MG-QoL-15r change from baseline at week 13 by arm with placebo-adjusted differences
| Measure at week 13 | Placebo (N=22) | Claseprubart 300 mg Q2W (N=21), absolute | Claseprubart 300 mg Q2W, placebo-adjusted (one-sided P) | Claseprubart 600 mg Q2W (N=22), absolute | Claseprubart 600 mg Q2W, placebo-adjusted (one-sided P) |
|---|---|---|---|---|---|
| MG-QoL-15r mean change from baseline | “-3.9” | “-6.1” | “-2.2 (P=0.0414)” | “-5.4” | “-1.5 (P=0.1122)” |
MG-QoL-15r change from baseline with standard deviations
Safety results
Safety and tolerability during the 13-week randomized controlled period
| Event, n (%) | Placebo (n=22) | Claseprubart 300 mg Q2W (n=21) | Claseprubart 600 mg Q2W (n=22) |
|---|---|---|---|
| Any treatment-related AEs | “13 (59.1)” | “15 (71.4)” | “21 (95.5)” |
| Clinical AEs | “11 (50.0%)” | “13 (61.9%)” | “15 (68.2%)” |
| Treatment-related serious AEs | “1 (4.5%)” | “0 (0%)” | “0 (0%)” |
| Infections | “10 (45.5%)” | “5 (23.8%)” | “6 (27.3%)” |
| Treatment-related serious infections | “1 (4.5%)” | “0 (0%)” | “0 (0%)” |
| Injection site reactions | “0 (0%)” | “2 (9.5%)” | “2 (9.1%)” |
| Newly positive for ANA | “0 (0%)” | “1 (5.9%)” | “8 (36.4%)” |
| Rashes | “0 (0%)” | “0 (0%)” | “0 (0%)” |
| Arthralgia | “1 (4.5%)” | “1 (4.8%)” | “0 (0%)” |
Table footnotes: clinical adverse events, injection site reactions, and antinuclear antibodies
Severity of treatment-related adverse events, serious adverse events, infections, and autoimmune activation
Most common adverse events in more than 5% of participants in any arm
| Adverse event, n (%) | Placebo (N=22) | Claseprubart 300 mg Q2W (n=21) | Claseprubart 600 mg Q2W (n=22) |
|---|---|---|---|
| Nasopharyngitis | “1 (4.5)” | “3 (14.3%)” | “3 (13.6)” |
| Lipase increased | “0 (0%)” | “3 (14.3%)” | “2 (9.1%)” |
| Upper respiratory tract infection | “3 (13.6%)” | “0 (0%)” | “1 (4.5%)” |
| Sinusitis | “2 (9.1%)” | “0 (0%)” | “0 (0%)” |
| Headache | “2 (9.1%)” | “0 (0%)” | “0 (0%)” |
| Diarrhea | “2 (9.1%)” | “0 (0%)” | “0 (0%)” |
Myasthenia gravis exacerbations in the randomized controlled period
| Event, n (%) | Placebo (N=22) | Claseprubart 300 mg Q2W (n=21) | Claseprubart 600 mg Q2W (n=22) |
|---|---|---|---|
| Myasthenia gravis exacerbations | “2 (9.1%)” | “2 (9.5%)” | “2 (9.1%)” |
Definition and management of myasthenia gravis exacerbations
Infections, autoimmune symptoms, and injection site reactions reported with top-line results
Injection site reaction severity in the top-line abstract
Open-label extension: adverse events through 52 weeks compared with the randomized controlled period
| Adverse event, n (%) | Randomized period: placebo (n=22) | Randomized period: pooled claseprubart (n=43) | Open-label extension: all claseprubart (n=60) |
|---|---|---|---|
| Clinical AEs | “11 (50.0)” | “28 (65.1)” | “45 (75.0)” |
| Related serious AEs | “1 (4.5)” | “0 (0.0)” | “1 (1.7)” |
| Discontinuation due to related AE | “0 (0)” | “0 (0)” | “1 (1.7)” |
| Infections | “10 (45.5)” | “11 (25.6)” | “28 (46.7)” |
| Related serious infections | “1 (4.5)” | “0 (0)” | “1 (1.7)” |
| Injection site reaction | “0 (0)” | “4 (9.3)” | “1 (1.7)” |
| Arthralgia | “1 (4.5)” | “1 (1.7)” | “4 (6.7)” |
| Myasthenia gravis exacerbation | “2 (9.1)” | “4 (9.3)” | “7 (11.7)” |
Open-label extension: table footnotes on the serious infection, discontinuation, and exacerbations
Open-label extension: consistency with the randomized period, meningococcal infections, and one death
Study limitations
Summary
MaGic is a phase 2 trial in which 65 participants with acetylcholine receptor antibody-positive generalized myasthenia gravis were randomized 1:1:1 to claseprubart 300 mg every 2 weeks (21 participants), claseprubart 600 mg every 2 weeks (22 participants), or placebo (22 participants) for 13 weeks. The primary endpoint was safety and tolerability, measured as the incidence of treatment-emergent adverse events and serious adverse events to week 13; MG-ADL, QMG, and MGC were secondary endpoints, and minimal symptom expression and MG-QoL-15r were exploratory. Efficacy comparisons with placebo used one-sided P values, with values below 0.1 considered nominally significant, the MG-ADL result in participants with a baseline QMG score of 10 or higher came from a post hoc analysis of 18 and 16 participants, and the open-label extension pooled both dose groups without a placebo comparison after week 13. The results reported through November 2026 appear in company press releases and presentations and in congress posters and abstracts, and no peer-reviewed full article reporting the trial was identified.